Trial Profile
An Open-Label, Single-dose, Non-Randomized, Safety and Tolerability Study of Recombinant Human Papillomavirus Virus 16/18 Bivalent Vaccine (E.Coli)in Healthy Female Subjects Aged 18 to 55 Years
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 17 Jan 2024
Price :
$35
*
At a glance
- Drugs Human papillomavirus 16/18 vaccine recombinant bivalent Xiamen Innovax (Primary)
- Indications Cervical cancer; Human papillomavirus infections
- Focus Adverse reactions
- 22 Apr 2014 Status changed from recruiting to completed as reported by ClinicalTrial.gov.
- 24 Dec 2010 New trial record